Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept

IntroductionHepatitis B virus (HBV) reactivation in kidney transplant recipients has been reported 3% to 9% of anti-HBc antibody (HBcAb)-positive HBs antigen (HBsAg)-negative patients. It not studied patients receiving belatacept, a selective costimulation blocker.MethodsWe performed retrospective study all belatacept 2 transplantation centers France. Among HBcAb-positive patients, we analyzed HBV rate, outcomes, and risk factors.ResultsA total 135 treated with were included: 32 HBsAg-positive. Seven reactivated (21.9% patients), including 5 HBsAg-negative (16.7% patients). Reactivation occurred 54.8 (± 70.9) months after transplantation. One patient presented severe hepatitis 1 developed cirrhosis. There was no significant difference survival between that did not: 5-year 100% (28.6; 100) 83.4% (67.6; 100), respectively (P = 0.363); graft 79.8% (61.7; 0.335). No factor, HBsAb positivity antiviral prophylaxis, statistically associated the reactivation.ConclusionHBV rate high when compared previous studies. impact survival. Further studies are needed confirm these results. A systematic prophylaxis for should be considered evaluated. Hepatitis blocker. We factors. reactivation.